Chinese medical-equipment maker producing hospital sterilization, disinfection and clinical laboratory instruments.
Chinese medical-equipment maker producing hospital sterilization, disinfection and clinical laboratory instruments.
Sells sterilisers and lab instruments to hospitals mainly through public tenders, so orders follow hospital budgets and equipment-upgrade programmes. Once equipment is installed, spare parts and service bring repeat income, and drug makers buy its packaging and sterilisation lines.
In one line: A Chinese STERIS Corporation (sterilization equipment).
Moat: narrow (installed base, regulatory licence). Long hospital installed base and medical-device registration approvals favor an incumbent.
Headquarters: Zibo, Shandong, China · Employees: 7,982
Size Shinva Medical Instrument (600587.SS) is a China Health Care company (Medical Distributors) with a market value of $1.10B, the 1979th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.09 on 18 Nov 2026.
Performance Over six months the shares fell 10.4%, against -2.3% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 5.8% over the last twelve months (peer median +5.0%); the operating margin is 5.2% (peer median 2.3%).
Valuation It trades at 13.4× forward earnings against a peer median of 15.8× (4th cheapest of 12).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.6 points above its cost of capital (6.2% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥10.1B | CN¥9.70B | CN¥9.95B | CN¥9.93B | CN¥9.24B |
| Revenue growth | — | -3% | 0% | +7% | — |
| Gross profit | CN¥2.65B | CN¥2.33B | CN¥2.47B | CN¥2.50B | CN¥2.35B |
| EBITDA | n/a | CN¥807M | CN¥950M | CN¥917M | CN¥812M |
| Net income | CN¥453M | CN¥526M | CN¥692M | CN¥654M | CN¥500M |
| Free cash flow | CN¥647M | CN¥408M | CN¥88.5M | CN¥511M | CN¥146M |
| Capital expenditure | CN¥150M | CN¥382M | CN¥421M | CN¥536M | CN¥248M |
| Total debt | CN¥1.49B | CN¥1.56B | CN¥1.59B | CN¥1.54B | CN¥1.90B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shinva Medical Instrument 600587.SS | $1.10B | -10% | +6% | 5% | 13.4× | -6.9% |
| Steris STE | $25.2B | +21% | +8% | 20% | 21.9× | 14.0% |
| Getinge GETI-B.ST | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600587.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.8% | -0.1% | 5th lowest of 21 |
| 6-month return | -10.4% | -2.3% | 7th lowest of 21 |
| Distance from 52-week high | -30.0% | -18.5% | 7th lowest of 21 |
| Revenue growth (TTM) | +5.8% | +5.0% | 10th highest of 21 |
| Operating margin | 5.2% | 2.3% | 5th highest of 21 |
| Forward P/E | 13.4× | 15.8× | 4th cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | -6.9% | -0.5% | 4th least demanding of 17 |
| Growth delivered (Del g) | +1.2% | +6.9% | 3rd lowest of 17 |
| Hurdle (Req g minus delivered) | -8.1 pp | -5.8 pp | 7th least demanding of 17 |
| ROIC minus cost of capital | +1.6 pp | +0.3 pp | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 13.4× | -6.9% | +1.2% |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% | +6.3% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | n/a | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | n/a | -2.7% | +17.9% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | n/a | n/a | n/a |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 9.5× | -9.7% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 21.1× | -1.0% | +3.9% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 47.7× | 24.7% | +29.9% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $897M | -24% | -5% | -2% | 7.7× | 17.0% | +12.4% |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 14.6× | -14.5% | +7.6% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | n/a | n/a | n/a |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 15.3× | 5.3% | +8.1% |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 22.2× | -4.6% | +5.1% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 12.0× | -6.2% | +3.8% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | n/a | -1.6% | +1.0% |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | n/a | 13.1% | +7.5% |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 15.8× | -10.4% | +3.2% |
| Hanmi Science 008930.KS | South Korea | $2.58B | +48% | +6% | 4% | n/a | 26.0% | +9.6% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | n/a | 21.1% | -18.1% |
| Asker Healthcare ASKER.ST | Sweden | $2.69B | -14% | +12% | 7% | 24.8× | 4.7% | +12.7% |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | n/a | n/a | n/a |